Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...
Deutsche Telekom is making a major push into artificial intelligence (AI) infrastructure, teaming up with US chipmaker Nvidia ...
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...
SFL Corporation Ltd. ("SFL" or the “Company”) (NYSE: SFL) plans to release its preliminary financial results for the third ...
In the AI bubble, total market valuations are in nosebleed territory, total market concentration is extreme. But there are ...
AI-driven precision-oncology analysis identifies patient subtypes with potential enhanced response to glufosfamide ...
Comparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth maintained, in contrast to growth suppression commonly seen with standard of care corticosteroids ...
"This year’s Incyte presentations highlight the potential of our portfolio to transform the treatment of blood cancers, specifically for patients with myeloproliferative neoplasms," said Pablo J.
From reference managers to note-taking apps, and presentation tools, the research and writing process is getting a high-tech ...
Prelude Therapeutics Incorporated continues to explore the SMARCA2 anticancer approach. Click here to read why PRLD stock is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback